TauRx Completes $135 Million Financing for Alzheimer Drug

TauRx Pharmaceuticals, a Singapore biopharmaceutical company, completes $135 million equity financing through a combination of new investors and existing shareholders. The funds will support development of its lead compound, LMTX® that is currently in Phase III clinical trials for Alzheimer's disease and Frontotemporal Dementia (FTD) in over 20 countries and 17,000 subjects. TauRx's website lists Temasek (Singapore’s sovereign wealth investment organization), the Development Bank of Singapore, the Dundee Corporation of Canada, as well as the Genting group of companies as investors. More details.... Share this with colleagues: // //